The goal of this learning activity is to provide doctors with a comprehensive review of the impact of subtype-selective α1-adrenergic receptor ( α1AR) antagonists in the treatment of benign prostatic hyperplasia (BPH).
Upon completing this module, participants will have a better understanding of the following aspects:
• Epidemiology of BPH
• Pathophysiology of BPH
• Evaluation and management of lower urinary tract symptoms (LUTS)
• Safety and efficacy of selective α1AAR antagonists
Professor Dr Ong Teng Aik
Head of the Division of Urology
University Malaya Medical Centre
Please read thoroughly & understand the module before attempting the assessment questions.
Terms & Conditions:
■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point.
■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points.
The modules/articles are best viewed with:
Google Chrome, Firefox, Internet Explorer, Safari or any other W3C standards compliant browser may be required to view the modules.